Blueprint Medicines Target Cancer with Genomics
Apr 20, 2011, 00:10 AM
by
Michael Croft
Technology Review | Blueprint Medicines, which announced $40 million in funding from Third Rock Ventures, is planning to develop drugs designed to target cancer cells with genomics.
April 20, 2011 | Blueprint Medicines, which announced $40 million in funding from Third Rock Ventures, is planning to develop drugs designed to target cancer cells with genomics. Founders include Gleevec developer and Cold Spring Harbor Laboratory Cancer Center. Technology Review